Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05691010
Other study ID # 22-405
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date January 10, 2023
Est. completion date January 10, 2025

Study information

Verified date March 2024
Source Memorial Sloan Kettering Cancer Center
Contact Kaled Alektiar, MD
Phone 212-639-7981
Email alektiak@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date January 10, 2025
Est. primary completion date January 10, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must have newly diagnosed endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma. - Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node surgical assessment (sentinel lymph node mapping and/or sampling). Para-aortic lymph node surgical assessment is optional. - Patients must have FIGO (2009) stage IIIA or IIIC1 disease (as determined by surgical staging). - Patients must consent to testing with MSK-IMPACT part A and are encouraged to consent to both parts A and C. - Age = 18 years. - Patients must have an Karnofsky Performance Status (KPS) = 70 (or ECOG 0 or 1). - Neurologic function: Neuropathy (sensory and motor) grade = 1. - No residual gross disease after surgery. - No prior radiation therapy or chemotherapy for treatment of endometrial cancer. - No active infection requiring antibiotics, except for uncomplicated urinary tract infection. - Patients must have adequate organ function, defined by the following laboratory results no more than 14 days prior to first study treatment: - Absolute neutrophil count (ANC) = 1500/mcL - Platelet count = 100,000/mcL - AST/ALT = 3X upper limit of normal (ULN) - Total bilirubin = 1.5X ULN. Patients with known Gilbert's disease and a total bilirubin = 3X ULN may be enrolled. - Creatinine = 1.5X ULN - Entry into study is limited to no more than 12 weeks from the date of surgery. - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. - Patients of childbearing age will by definition have undergone hysterectomy and bilateral oophorectomy prior to study enrollment. - Participants must agree not to breastfeed during the study or for 150 days after the last dose of study treatment. Exclusion Criteria: - Patients whose endometrial cancers harbor known pathogenic POLE mutations - Patients whose endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6 and/or MSI-H - Active inflammatory bowel disease, such as Crohn's disease or ulcerative colitis. - History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. This includes but is not limited to: uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, and superior vena cava syndrome. - Patients unfit for pelvic radiation therapy due to the following: - Has had radiation therapy encompassing >20% of the bone marrow within 2 weeks, or any radiation therapy within 1 week prior to day 1 of protocol therapy - Patients with a history of pelvic radiation. - Patients with a history or current diagnosis of a vesicovaginal, enterovaginal, or colovaginal fistula. - Any hematological abnormality or disorder that would be a contraindication to radiation per the treating physician.

Study Design


Intervention

Radiation:
Intensity-modulated radiation therapy
After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
Drug:
Carboplatin
Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
Paclitaxel
Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles

Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge (All protocol activities) Basking Ridge New Jersey
United States Memorial Sloan Kettering Commack (All protocol activities) Commack New York
United States Memorial Sloan Kettering Westchester (All protocol activities) Harrison New York
United States Memorial Sloan Kettering Monmouth (All protocol activities) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (All protocol activities) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center New York New York
United States Memorial Sloan Kettering Nassau (All protocol activities) Uniondale New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of integrated delivery of short-course IMRT with carboplatin/paclitaxel in patients with stage III endometrial cancer Feasibility of study treatment is defined as defined as the number of participants who complete all 6 planned cycles of carboplatin and paclitaxel with no delays in chemotherapy cycles greater than 21 days. up to 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05796518 - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors N/A
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06463028 - Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Completed NCT03820024 - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback N/A
Active, not recruiting NCT05082025 - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Phase 2
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Recruiting NCT04569773 - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Not yet recruiting NCT05998798 - Revealing Engagement Patterns Among Endometrial Cancer Patients
Not yet recruiting NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Phase 2
Not yet recruiting NCT06073184 - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Phase 2
Terminated NCT02907073 - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Phase 1/Phase 2
Completed NCT02413606 - ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? N/A